These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17138674)

  • 1. Long-term treprostinil in pulmonary arterial hypertension: Is the glass half full or half empty?
    Provencher S
    Eur Respir J; 2006 Dec; 28(6):1073-5. PubMed ID: 17138674
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
    Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
    Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
    Barst RJ; Galie N; Naeije R; Simonneau G; Jeffs R; Arneson C; Rubin LJ
    Eur Respir J; 2006 Dec; 28(6):1195-203. PubMed ID: 16899485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension.
    El-Kersh K; Smith JS
    Am J Ther; 2017; 24(5):e620-e621. PubMed ID: 27574945
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    Poms A; Kingman M
    Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
    Ivy DD; Claussen L; Doran A
    Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
    Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
    Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.
    Herald N; Laliberte K
    Pharmacotherapy; 2006 Aug; 26(8):1203; discussion 1203-4. PubMed ID: 16863500
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining treprostinil and sildenafil in the treatment of pulmonary hypertension.
    Chua R; Keogh A
    Intern Med J; 2005 Nov; 35(11):684-5. PubMed ID: 16248867
    [No Abstract]   [Full Text] [Related]  

  • 17. The globalization of clinical trials in pulmonary arterial hypertension.
    Park MH; Rubin LJ
    J Heart Lung Transplant; 2010 Feb; 29(2):157-8. PubMed ID: 20113908
    [No Abstract]   [Full Text] [Related]  

  • 18. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.
    Levy M; Celermajer DS; Bourges-Petit E; Del Cerro MJ; Bajolle F; Bonnet D
    J Pediatr; 2011 Apr; 158(4):584-8. PubMed ID: 21035821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension.
    Rich JD; Glassner C; Wade M; Coslet S; Arneson C; Doran A; Gomberg-Maitland M
    Chest; 2012 Jan; 141(1):36-42. PubMed ID: 21659437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.